Target: ₹1,315
CMP: ₹1,281.95
We interacted with Dr Reddy’s Lab Head of IR, Aishwarya Sitharam, following the company’s successful day-1 launch of Semaglutide. Dr Reddy’s Lab is the first to introduce a DCGI-approved version in India under the brand name Obeda, establishing an early-mover advantage in the domestic GLP-1 market.
Semaglutide is a complex peptide product and not a simple smallmolecule generic and hence requires advanced manufacturing capabilities and sterile production expertise.
The company’s premium pricing at ₹4,200 per month versus peers at ₹1,300 reflects its dosage form, with a prefilled disposable pen format as compared to vial-based alternatives, which could support greater physician preference and patient stickiness. The management has indicated that it is unlikely to engage in aggressive price cuts to drive volumes.
We view this launch as positioning the company strategically within the emerging GLP-1 opportunity, with a differentiated focus on quality, delivery format and brand trust rather than price-led competition.
Overall, in the medium term, we expect a shift towards a more consolidated, quality-led market, with Dr Reddy’s Lab well-placed to benefit given its early entry and manufacturing strengths. Profitability is likely to improve as the business scales up and operating leverage kicks in.